Karyopharm Therapeutics Inc.
KPTI · Pharmaceutical Preparations · 22.7M shares · -53%/yr ↓ buyback · EDGAR filings ↗
Reference price $9.50 · est. market cap ~$215M — last insider sale, 2026-05-14 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Commercial-stage (XPOVIO) but going-concern, with cash only into Q2 2026 and a long trail of failed selinexor trials.
Strengths
- Marketed product XPOVIO with a positive, significant Phase 3 BOSTON readout (HR 0.70, p=0.0075) underpinning approval
- Operating margin ~60th pct relative to sector
Risks
- Explicit going concern; runway only 3.4 quarters (28th pct), current ratio 1.12 (15th pct), ROA -1.8 (13th pct)
- Numerous negative/terminated Phase 2/3 readouts (COVID, AML, prostate, SCC, Richter's, melanoma) limiting label expansion
Notable findings
- Going concern• In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have of Financial Condition and Results of Operations ”, below for a further d
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Net lossNet loss (net margin -134.2%)
- Cash burnNegative free cash flow (-75.4M)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Buying back stockNet buyback — share count -53%/yr over 3y
- New fund positionNotable fund(s) opened this quarter: GOLDMAN SACHS GROUP INC
- Insider sellingInsider selling — 17 open-market sale(s) by 7 insider(s) (cluster of 7 insiders, ~$347,929, last 6mo) Form 4 ↗
- Trial readout soonUpcoming trial readout ~2026-08 — PHASE3 · Endometrial Cancer
- Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗
- Notable holderHeld by 5 notable fund(s): GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-62.1%
Net margin
-134.2%
Return on equity
66.9%
Return on assets
-180.8%
Revenue growth (QoQ)
2.9%
Current ratio
1.1×
Free cash flow
-$75M
Tangible book value
-$293M
Cash & investments
$64M
Cash runway
3q
Stock comp / revenue
9.6%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-21 | Oliger Christy J. | Grant | 16K | — |
| 2026-05-21 | Schor Chen | Grant | 16K | — |
| 2026-05-21 | Greene Barry E | Grant | 16K | — |
| 2026-05-21 | PAKIANATHAN DEEPIKA | Grant | 16K | — |
| 2026-05-21 | Su Zhen | Grant | 16K | — |
| 2026-05-21 | BOHLIN GAREN G | Grant | 16K | — |
| 2026-05-14 | Mano Michael | Sell | 266 | $9.50 |
| 2026-05-14 | Poulton Stuart | Sell | 403 | $9.50 |
| 2026-05-14 | Rangwala Reshma | Sell | 408 | $9.50 |
| 2026-05-14 | Cheng Sohanya Roshan | Sell | 324 | $9.50 |
| 2026-05-14 | Abate Kristin | Sell | 53 | $9.50 |
| 2026-05-14 | Paulson Richard A. | Sell | 2.2K | $9.50 |
| 2026-05-13 | Abate Kristin | Grant | 121 | — |
| 2026-05-13 | Mano Michael | Grant | 700 | — |
| 2026-05-13 | Rangwala Reshma | Grant | 947 | — |
| 2026-05-13 | Paulson Richard A. | Grant | 4.9K | — |
| 2026-05-13 | Cheng Sohanya Roshan | Grant | 947 | — |
| 2026-05-13 | Poulton Stuart | Grant | 896 | — |
| 2026-04-21 | Rangwala Reshma | Sell | 449 | $8.94 |
| 2026-03-02 | Abate Kristin | Sell | 559 | $9.41 |
| 2026-03-02 | Poulton Stuart | Sell | 5.1K | $9.41 |
| 2026-03-02 | Cheng Sohanya Roshan | Sell | 4.6K | $9.41 |
| 2026-03-02 | Mano Michael | Sell | 3.5K | $9.41 |
| 2026-03-02 | Rangwala Reshma | Sell | 5.1K | $9.41 |
| 2026-03-02 | Paulson Richard A. | Sell | 12K | $9.41 |
| 2026-02-17 | Poulton Stuart | Sell | 378 | $8.63 |
| 2026-02-05 | Paulson Richard A. | Grant | 81K | — |
| 2026-02-03 | Macomber Lori | Sell | 1.6K | $6.30 |
| 2026-01-31 | Cheng Sohanya Roshan | Grant | 32K | — |
| 2026-01-31 | Rangwala Reshma | Grant | 32K | — |
| 2026-01-31 | Macomber Lori | Grant | 32K | — |
| 2026-01-31 | Mano Michael | Grant | 32K | — |
| 2026-01-31 | Poulton Stuart | Grant | 32K | — |
| 2026-01-28 | Abate Kristin | Sell | 50 | $7.03 |
| 2026-01-27 | Abate Kristin | Grant | 92 | — |
| 2026-01-21 | Abate Kristin | Sell | 265 | $5.96 |
| 2025-10-15 | Cheng Sohanya Roshan | Grant | 44K | — |
| 2025-10-15 | Abate Kristin | Grant | 13K | — |
| 2025-10-15 | Poulton Stuart | Grant | 40K | — |
| 2025-10-15 | Mano Michael | Grant | 44K | — |
| 2025-10-15 | Paulson Richard A. | Grant | 114K | — |
| 2025-10-15 | Macomber Lori | Grant | 44K | — |
| 2025-10-01 | Abate Kristin | Sell | 362 | $6.30 |
| 2025-09-15 | Rangwala Reshma | Sell | 408 | $6.43 |
| 2025-09-15 | Mano Michael | Sell | 234 | $6.43 |
| 2025-09-15 | Paulson Richard A. | Sell | 1.3K | $6.43 |
| 2025-09-15 | Abate Kristin | Sell | 23 | $6.43 |
| 2025-09-15 | Poulton Stuart | Sell | 401 | $6.43 |
| 2025-09-15 | Cheng Sohanya Roshan | Sell | 325 | $6.43 |
| 2025-09-12 | Cheng Sohanya Roshan | Grant | 945 | — |
| 2025-09-12 | Paulson Richard A. | Grant | 2.8K | — |
| 2025-09-12 | Mano Michael | Grant | 612 | — |
| 2025-09-12 | Poulton Stuart | Grant | 888 | — |
| 2025-09-12 | Rangwala Reshma | Grant | 945 | — |
| 2025-09-12 | Abate Kristin | Grant | 46 | — |
| 2025-09-03 | Abate Kristin | Sell | 12 | $6.78 |
| 2025-07-29 | Poulton Stuart | Sell | 191 | $4.37 |
| 2025-07-22 | Abate Kristin | Sell | 238 | $4.00 |
| 2025-05-06 | Paulson Richard A. | Sell | 236 | $7.12 |
| 2025-04-23 | Rangwala Reshma | Sell | 419 | $6.17 |
| 2025-04-04 | Paulson Richard A. | Sell | 245 | $3.74 |
| 2025-03-04 | Cheng Sohanya Roshan | Sell | 3.4K | $6.29 |
| 2025-03-04 | Paulson Richard A. | Sell | 12K | $6.29 |
| 2025-03-04 | Rangwala Reshma | Sell | 3.6K | $6.29 |
| 2025-03-04 | Poulton Stuart | Sell | 3.5K | $6.29 |
| 2025-03-04 | Abate Kristin | Sell | 571 | $6.29 |
| 2025-03-04 | Mano Michael | Sell | 2.8K | $6.29 |
| 2025-02-28 | Cheng Sohanya Roshan | Grant | 5.4K | — |
| 2025-02-28 | Cheng Sohanya Roshan | Grant | 4.6K | — |
| 2025-02-28 | Rangwala Reshma | Grant | 5.4K | — |
| 2025-02-28 | Rangwala Reshma | Grant | 4.6K | — |
| 2025-02-28 | Poulton Stuart | Grant | 5.0K | — |
| 2025-02-28 | Poulton Stuart | Grant | 4.6K | — |
| 2025-02-28 | Abate Kristin | Grant | 933 | — |
| 2025-02-28 | Paulson Richard A. | Grant | 20K | — |
| 2025-02-28 | Mano Michael | Grant | 3.3K | — |
| 2025-02-28 | Mano Michael | Grant | 2.2K | — |
| 2025-02-18 | Poulton Stuart | Sell | 5.9K | $0.63 |
| 2025-02-04 | Paulson Richard A. | Sell | 4.1K | $0.65 |
| 2025-01-31 | Macomber Lori | Grant | 160K | — |
| 2025-01-06 | Paulson Richard A. | Sell | 4.1K | $0.78 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT04414475 ↗ | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. Multiple Myeloma, Refractory | PHASE2 | Recruiting | 2028-01-01 |
| NCT05980806 ↗ | A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia Myelofibrosis, Moderate Thrombocytopenia | PHASE2 | Recruiting | 2027-06-01 |
| NCT02343042 ↗ | Selinexor and Backbone Treatments of Multiple Myeloma Patients Multiple Myeloma | PHASE1/PHASE2 | Active Not Recruiting | 2027-04-01 |
| NCT02227251 ↗ | Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Diffuse Large B-cell Lymphoma | PHASE2 | Active Not Recruiting | 2026-12-01 |
| NCT04442022 ↗ | A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Relapsed/Refractory Diffuse Large B-cell Lymphoma | PHASE2/PHASE3 | Active Not Recruiting | 2026-12-01 |
| NCT04562870 ↗ | A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis Myelofibrosis | PHASE2 | Active Not Recruiting | 2026-09-01 |
| NCT05611931 ↗ | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma Endometrial Cancer | PHASE3 | Active Not Recruiting | 2026-08-01 |
| NCT04562389 ↗ | Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Myelofibrosis | PHASE3 | Active Not Recruiting | 2026-02-20 |
| NCT04607772 ↗ | Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL) Relapsed or Refractory Diffuse Large B-Cell Lymphoma | PHASE1/PHASE2 | Withdrawn | 2025-12-01 |
| NCT02649790 ↗ | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC) | PHASE1/PHASE2 | Completed | 2024-08-31 |
| NCT04256707 ↗ | Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment Non-Small Cell Lung Carcinoma (NSCLC), Colorectal Cancer (CRC) | PHASE1/PHASE2 | Completed | 2024-07-31 |
| NCT04768881 ↗ | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma Locally Advanced Unresectable or Metastatic Melanoma | PHASE2 | Terminated | 2023-09-22 |
| NCT04421378 ↗ | A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma Glioblastoma Multiforme | PHASE1/PHASE2 | Terminated | 2023-07-03 |
| NCT04854434 ↗ | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations Metastatic Colorectal Cancer | PHASE2 | Terminated | 2022-06-24 |
| NCT03555422 ↗ | Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] Endometrial Cancer | PHASE3 | Completed | 2022-01-22 |
| NCT02702492 ↗ | PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA) Solid Tumors, NHL | PHASE1 | Terminated | 2021-01-26 |
| NCT02606461 ↗ | Selinexor in Advanced Liposarcoma Dedifferentiated Liposarcoma | PHASE2/PHASE3 | Completed | 2020-10-28 |
| NCT04349098 ↗ | Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection Coronavirus Infection | PHASE2 | Completed | 2020-10-05 |
| NCT04355676 ↗ | Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 Coronavirus Infection | PHASE2 | Withdrawn | 2020-08-30 |
| NCT03110562 ↗ | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma Multiple Myeloma | PHASE3 | Completed | 2020-02-18 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-05-28 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-14 | ResultsExhibits | filing ↗ |
| 2026-03-27 | Other | filing ↗ |
| 2026-03-24 | Material agreement3.02Reg FDOtherExhibits | filing ↗ |
| 2026-03-03 | Material agreementOtherExhibits | filing ↗ |
| 2026-02-19 | Shareholder vote | filing ↗ |
| 2026-02-12 | ResultsExhibits | filing ↗ |
| 2026-01-12 | ResultsOtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-28 | 2026-05-21 | 0001503802-26-000027 ↗ |
| 10-Q | 2026-05-14 | 2026-03-31 | 0001193125-26-222827 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001193125-26-222808 ↗ |
| 8-K | 2026-03-27 | 2026-03-27 | 0001503802-26-000011 ↗ |
| 8-K | 2026-03-24 | 2026-03-24 | 0001193125-26-120770 ↗ |
| 8-K | 2026-03-03 | 2026-02-27 | 0001503802-26-000006 ↗ |
| 8-K | 2026-02-19 | 2026-02-18 | 0001193125-26-059349 ↗ |
| 10-K | 2026-02-13 | 2025-12-31 | 0001193125-26-049397 ↗ |
| 8-K | 2026-02-12 | 2026-02-12 | 0001193125-26-047670 ↗ |
| 8-K | 2026-01-12 | 2026-01-12 | 0001193125-26-009738 ↗ |
| 10-Q | 2025-11-03 | 2025-09-30 | 0001193125-25-261667 ↗ |
| 8-K | 2025-11-03 | 2025-11-03 | 0001193125-25-261663 ↗ |